Molecular Health and Axxam Announce Strategic Partnership in Drug Development

Molecular Health GmbH and Axxam S.p.A. have entered a strategic partnership to enhance the process of identifying innovative drug targets. This collaboration aims to merge data-driven insights with biological validation to assist biopharmaceutical companies in confirming relevant drug leads. By integrating Molecular Health’s Dataome with Axxam’s DiscoveryMAXX, the partnership seeks to provide precise disease-to-target and target-to-lead solutions.

Dataome’s AI capabilities will be utilized to analyze complex datasets, allowing for the identification of high-potential drug targets. These targets will then undergo rigorous experimental validation within Axxam’s platform. According to Ciriaco Maraschiello and Friedrich von Bohlen, the partnership is set to improve efficiency and decision-making in early drug discovery. By bridging AI predictions and biological insights, the collaboration aims to offer next-generation discovery programs to pharmaceutical innovators worldwide.